Cantor Fitzgerald Downgrades BioDelivery Sciences International (BDSI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
May 10, 2016 7:00 AM EDTRALEIGH, N.C., May 10, 2016 /PRNewswire/ --
Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017 BUNAVAIL prescriptions increase 180% compared to first quarter of 2015; over 350 new prescribers added in first quarter of 2016 BUNAVAIL net revenue increased 41% in first quarter compared to fourth quarter 2015 BUNAVAIL revenue per prescription increased more than 20% in the first quarter compared to fourth quarter 2015 Strong cash position of $69.4... More